511 related articles for article (PubMed ID: 23741305)
1. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.
Huls MH; Figliola MJ; Dawson MJ; Olivares S; Kebriaei P; Shpall EJ; Champlin RE; Singh H; Cooper LJ
J Vis Exp; 2013 Feb; (72):e50070. PubMed ID: 23407473
[TBL] [Abstract][Full Text] [Related]
3. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
[TBL] [Abstract][Full Text] [Related]
4. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.
Kebriaei P; Huls H; Jena B; Munsell M; Jackson R; Lee DA; Hackett PB; Rondon G; Shpall E; Champlin RE; Cooper LJ
Hum Gene Ther; 2012 May; 23(5):444-50. PubMed ID: 22107246
[TBL] [Abstract][Full Text] [Related]
5. Sleeping beauty system to redirect T-cell specificity for human applications.
Maiti SN; Huls H; Singh H; Dawson M; Figliola M; Olivares S; Rao P; Zhao YJ; Multani A; Yang G; Zhang L; Crossland D; Ang S; Torikai H; Rabinovich B; Lee DA; Kebriaei P; Hackett P; Champlin RE; Cooper LJ
J Immunother; 2013 Feb; 36(2):112-23. PubMed ID: 23377665
[TBL] [Abstract][Full Text] [Related]
6. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
[TBL] [Abstract][Full Text] [Related]
7. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.
Manuri PV; Wilson MH; Maiti SN; Mi T; Singh H; Olivares S; Dawson MJ; Huls H; Lee DA; Rao PH; Kaminski JM; Nakazawa Y; Gottschalk S; Kebriaei P; Shpall EJ; Champlin RE; Cooper LJ
Hum Gene Ther; 2010 Apr; 21(4):427-37. PubMed ID: 19905893
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
10. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
Singh H; Huls H; Kebriaei P; Cooper LJ
Immunol Rev; 2014 Jan; 257(1):181-90. PubMed ID: 24329797
[TBL] [Abstract][Full Text] [Related]
11. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
12. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
[TBL] [Abstract][Full Text] [Related]
13. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.
Singh H; Manuri PR; Olivares S; Dara N; Dawson MJ; Huls H; Hackett PB; Kohn DB; Shpall EJ; Champlin RE; Cooper LJ
Cancer Res; 2008 Apr; 68(8):2961-71. PubMed ID: 18413766
[TBL] [Abstract][Full Text] [Related]
14. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.
Chicaybam L; Abdo L; Bonamino MH
Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672
[TBL] [Abstract][Full Text] [Related]
15. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
[TBL] [Abstract][Full Text] [Related]
16. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
Singh H; Moyes JS; Huls MH; Cooper LJ
Cancer Gene Ther; 2015 Mar; 22(2):95-100. PubMed ID: 25591810
[TBL] [Abstract][Full Text] [Related]
17. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Oluwole OO; Davila ML
J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
[TBL] [Abstract][Full Text] [Related]
18. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
19. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
[TBL] [Abstract][Full Text] [Related]
20. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]